PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program (PANDIA_IRIS)
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
About this trial
This is an interventional supportive care trial for Diabetes Mellitus, Type 2 focused on measuring Medication adherence, Diabetes Mellitus, Renal Insufficiency, Chronic, Interprofessional Relations
Eligibility Criteria
Inclusion criteria:
- MDRD or CKD-EPI eGFR ≤60 ml/min/1.73m2 or albumin/creatinin >30mg/mmol
- Type 2 diabetes
- At least one medication in the following list : oral antidiabetics and/or statins and/or antihypertensive drugs and/or aspirin
- Patients speaking french, english or italian or interpreter present at each pharmacy visit
- Patients have to sign the written consent form
- Patients have to agree to use the Electronic Monitoring system (EM, named MEMS®; Aardex Ltd)
- Complete laboratory exams in the last 6 months: eGFR and HbA1c and (albumin/creatinin ratio or total cholesterol + LDL + HDL)
Exclusion Criteria:
- Not being able to understand or sign the consent form
- Pregnancy
- Recent cancer diagnosis
- Cognitive disorder
- The subject does not manage the treatment alone
Sites / Locations
- Centre Hospitalier Universitaire Vaudois
- Unisante
Arms of the Study
Arm 1
Arm 2
Other
Other
Intervention group A
Intervention group B
Intervention group A will benefit of the medication adherence support program during 12 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
Intervention group A will benefit of the medication adherence support program during 6 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals